Skip to main content
. 2019 Nov 13;3(11):e10233. doi: 10.1002/jbm4.10233

Figure 3.

Figure 3

ICER = incremental cost‐effectiveness ratio, QALY = quality‐adjusted life year. The results of deterministic sensitivity analyses for the three most‐influential parameters other than the cost of teriparatide. The figures present the ICERs of sequential teriparatide/alendronate compared with alendronate alone, when the indicated model parameters are varied across their ranges from a societal perspective. The bolded vertical line represents the ICER of $150,000 per QALY. We present the three largest changes of ICERs compared with base case parameter estimates.